Manufacturers are seeing a steady rise in requests to reformulate these potent actives; sometimes it’s to address new cancer types, other times it’s to change delivery routes from, for example, injectable to oral.
These shifts, although subtle, are symptomatic of broader changes in drug development: there’s a greater emphasis on speed and cost-efficiency.
Dr Kevin Robinson spoke to K.H. Honneshaiah (KHH), Head of API and Chief Operating Officer, Shilpa Pharma Life Sciences, to find out more.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.
